Chemomab Therapeutics (NASDAQ:CMMB) Trading Down 2.2% – Should You Sell?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) shares were down 2.2% during mid-day trading on Wednesday . The company traded as low as $2.59 and last traded at $2.69. Approximately 76,586 shares were traded during trading, a decline of 27% from the average session volume of 105,116 shares. The stock had previously closed at $2.75.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Chemomab Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Chemomab Therapeutics Stock Down 0.8%

The firm has a market cap of $18.70 million, a price-to-earnings ratio of -1.21 and a beta of 0.76. The business has a 50 day moving average of $2.01 and a 200 day moving average of $1.82.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Hedge Funds Weigh In On Chemomab Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Kestra Private Wealth Services LLC boosted its position in Chemomab Therapeutics by 19.3% during the first quarter. Kestra Private Wealth Services LLC now owns 61,710 shares of the company’s stock worth $97,000 after acquiring an additional 10,000 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Chemomab Therapeutics during the 4th quarter worth $31,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Chemomab Therapeutics during the fourth quarter worth $132,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.